JNJJanssen Research & Development, LLCSigning up patients
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 400 (planned)
- Started
- Feb 4, 2026
- Main results expected
- Dec 12, 2028
- Fully finished
- Sep 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response
Measured over: Up to 5 years and 7 months
Progression-Free Survival (PFS)
Measured over: Up to 5 years and 7 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07258511 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC